Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives. 2006

Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Departamento de Síntese Orgânica, Manguinhos, CEP 21041250, Rio de Janeiro, RJ, Brazil.

The aim of this work was to describe the synthesis, the in vitro anti-Mycobacterium tuberculosis profile, and the structure-activity relationship (SAR) study of new N-substituted-phenyl-1,2,3-triazole-4-carbaldehydes (3a-l). The reactions of aromatic amine hydrochlorides with diazomalonaldehyde (1) produced several N-substituted-phenyl-1,2,3-triazole-4-carbaldehydes (3a-l) in moderate-to-good yields. In order to investigate the influence of the difluoromethylene group on the anti-Mycobacterium activity of these compounds, fluorination of triazoles with DAST converted the corresponding carbaldehyde compounds into new difluoromethyl derivatives (4a-l) in excellent yield. Characterization of all compounds was achieved by spectroscopic means and additional for 1-(4-methylphenyl)-1,2,3-triazole-4-carbaldehyde, 3k by X-ray crystallography. Compounds (3a-l) and (4a-l) have been screened for the inhibitory activity against Mycobacterium tuberculosis H37Rv strain (ATCC 27294) and all of them were able to inhibit the growth of the bacterium. Interestingly, 3a and 3k exhibited the best inhibition with MIC values of 2.5mug/mL, similar to pharmaceuticals currently used in the treatment of tuberculosis. Our SAR study indicated the importance of the hydrogen bond acceptor subunit (3a-l), the position in the aromatic ring, the planarity of triazole and phenyl rings in these compounds, and a correlation between the uniform HOMO coefficient distribution and the anti-tubercular activity. The significant activity of 3a and 3k pointed them as promising lead molecules for further synthetic and biological exploration.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies

Related Publications

Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
September 2011, Bioorganic & medicinal chemistry,
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
May 2003, Bioorganic & medicinal chemistry,
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
January 2009, European journal of medicinal chemistry,
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
July 2013, Molecules (Basel, Switzerland),
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
January 2018, Molecules (Basel, Switzerland),
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
May 2021, Molecules (Basel, Switzerland),
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
June 2014, European journal of medicinal chemistry,
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
July 2014, European journal of medicinal chemistry,
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
November 2015, Chemical biology & drug design,
Marilia S Costa, and Núbia Boechat, and Erica A Rangel, and Fernando de C da Silva, and Alessandra M T de Souza, and Carlos R Rodrigues, and Helena C Castro, and Ivan N Junior, and Maria Cristina S Lourenço, and Solange M S V Wardell, and Vitor F Ferreira
January 2012, TheScientificWorldJournal,
Copied contents to your clipboard!